Quote

Quote

  • ・Only enter lowercase letters or numbers.
  • ・For KWE Waybill, do not include hyphen.

You will be redirected after selecting a country/region.

CO<sub>2</sub>Calculator

Calculator

Close

Customer Advisory

U.S. Expands Section 232 Tariffs on Metals and Pharmaceuticals

Apr. 8, 2026
Customer Advisory

The U.S. administration has announced significant updates to Section 232 tariff measures, expanding coverage across key industrial metals and initiating new actions targeting pharmaceutical imports. Recent guidance from U.S. Customs and Border Protection (CBP) provides additional clarification on implementation and scope, with metal tariff changes expected to take effect in early April.

Steel, Aluminum, and Copper Tariffs
A Proclamation issued April 2, 2026 revises how Section 232 tariffs are applied to imported steel, aluminum, and copper products. CBP has since issued implementation guidance confirming classification, valuation, and reporting expectations for affected imports.

Tariffs will now be assessed based on the full value of goods, with updated rates depending on material composition:

  • 50% tariffs on products made entirely or primarily of these metals
  • 25% tariffs on derivative products
  • 15% tariffs (through 2027) on certain industrial and grid-related equipment
  • Reduced 10% tariffs for products manufactured abroad using U.S.-origin metals
  • Items containing minimal metal content (≤15%) are excluded

Importers should expect increased scrutiny on product classification and declared value, as CBP begins enforcement under the updated framework. Additional technical guidance, including tariff applicability and reporting requirements, has been issued via CBP messaging.

Pharmaceutical and API Import Measures
A separate Section 232 action targets imported patented pharmaceuticals and active pharmaceutical ingredients (APIs), citing supply chain dependence and national security risks. Key provisions include:

  • 100% tariffs on certain patented pharmaceuticals and APIs
  • Reduced rates (e.g., 20%) for companies with approved U.S. onshoring plans, with escalation over time
  • Zero or reduced tariffs tied to specific trade agreements or pricing/onshoring commitments
  • Generic pharmaceuticals are currently excluded from these measures

These measures are not expected to take effect immediately, with additional implementation details and timelines to be provided. If you have any questions regarding how these developments may impact your shipments or supply chain, please contact your KWE representative.

Read more:

SIGN UP HERE – ONE FORWARDER, ONE BROKER = OVERALL COMPLIANCE

Back to Top

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the Cookie Setting to set. Please note that some cookies are necessary for the proper functioning of the website and cannot be disabled on our system.

  • These cookies are necessary for the website to function and cannot be switched off in our systems.